Mark N. Painter, CPMA, MBS

Mark N. Painter, CPMA, MBS

PRS Consulting, LLC

Thornton, Colorado

Mark N. Painter is a managing partner of PRS Consulting LLC, the CEO of PRS Urology Service Corporation, the Vice President of Coding and Reimbursement Information for Physician Reimbursement Systems, Inc., and CEO of Relative Value Studies, Inc. Since co-founding PRS in 1989, Mr. Painter has served as the primary coding resource for the PRS products currently produced and marketed in conjunction with 9 National Specialty Organizations including hotlines, coding manuals, and quick reference tools, the internet-based application codingtoday.com, and seminars. He has lectured to a variety of groups concerned with healthcare reimbursement. Mr. Painter’s extensive knowledge of physician documentation, as well as coding and reimbursement issues, has allowed him to assist insurance companies, physicians and their staff members, legal counsel, actuaries, specialty societies, consultants, and the medical industry on a daily basis. Mr. Painter has been the lead for the company on multiple corporate/physician integrity agreements serving as the Independent Review Organization (IRO), and has successfully overseen the review and continued participation in Medicare of several practices from multiple specialties. Mr. Painter has been commended for his education and direction for appropriate documentation and coding by multiple Medicare medical directors with whom he has shared the podium during national and regional medical meetings. He serves as an expert in legal counsel for bio device companies, medical directors, and pharmaceuticals.

Talks by Mark N. Painter, CPMA, MBS

2025 Medicare Part D Changes: Physician’s Perspective

Mark N. Painter, CPMA, MBS, Managing Partner, Consulting LLC, CEO, PRS Urology Service Corporation, Vice President of Coding and Reimbursement Information and CEO Relative Value Studies, Inc. is joined by Neal D. Shore, MD, FACS and David S. Morris, MD, FACS to discuss the physician’s perspective on the upcoming Medicare Part D updates. They share the benefits of these changes and the possible hardships as well.

In this third part of this series, Mark briefly highlights the Medicare Part D changes, such as the reduction of the maximum out-of-pocket expenditure and the Medicare Prescription Payment Plan (MPPP) or “smoothing option”, that the first part of this series covers in more detail. Neal D. Shore, MD, FACS and David S. Morris, MD, FACS then join Mark to share their point of view as physicians on how they are planning to maneuver these changes in the best way. David S. Morris, MD, FACS discusses how he thinks these changes will give a positive outlook to a patient’s finances, for example with the smoothing option or through grants. Also, Neal D. Shore, MD, FACS shares how offices have to prepare to help patients through the process of understanding and taking advantage of these upcoming updates.

This 15-minute discussion concludes with all speakers agreeing that the financial burden on the patient is key when it comes to medications, but they are cautiously optimistic that these upcoming changes will benefit patients, although many will still rely heavily on grants and funding to get the medications they need. Both physicians share in their hope that the upcoming Medicare Part D changes will be a step in the right direction to making healthcare more accessible to all patients and a reminder: Open Enrollment begins October 15, 2024, and runs through December 7, 2024.

Read More

2025 Medicare Part D Changes: Preparing Your Office and Patients

Mark N. Painter, CPMA and Michael Burnett, Chief Operating Officer at Kansas City Urology Care, discuss upcoming 2025 Medicare Part D changes and how it will affect urology patients. This 12-minute discussion goes into detail of each new update to Medicare Part D, how it can affect patients who are in need of grants, subsidies or assistance, and how urology practices can aid patients in adopting and taking advantage of these new updates.

Read More

2025 Medicare Part D Changes: Overview of the 2025 Plan

Mark N. Painter, CPMA, Managing Partner, Consulting LLC, CEO, PRS Urology Service Corporation, Vice President of Coding and Reimbursement Information and
CEO Relative Value Studies, Inc. reviews upcoming 2025 Medicare Part D changes and what they aim to achieve. This 13-minute discussion goes into detail of each new update to Medicare Part D, including the reduction of the maximum out-of-pocket expenditure, the Medicare Prescription Payment Plan (MPPP), and “Likely to Benefit Letter” and how these can affect different patients, including those that are eligible for grants or subsidies.
Dr. Pohlman then brings up emerging complementary tests that mitigate the weaknesses of PSA alone, like the EpiSwitch® Prostate Screening (PSE) Blood Test. He explains that the EpiSwitch® PSE combines five epigenetic biomarkers with a standard PSA test in prostate cancer screening. He briefly discusses how the simplified test can be implemented in practice and how the test results are quickly and clearly delivered in patient-friendly formats to facilitate shared decision-making.

Dr. Pohlman then discusses the validation processes behind the EpiSwitch® PSE test, including its high accuracy, specificity, sensitivity, and positive/negative predictive values, which reduce the need for unnecessary prostate biopsies. He presents data supporting the benefits of using non-invasive biomarker tests like the EpiSwitch® PSE test in prostate cancer screening prior to MRI and/or prostate biopsy.

Dr. Pohlman concludes by presenting case studies where the EpiSwitch® PSE test would have prevented unnecessary biopsies and MRIs. He discusses his practice’s success in using the EpiSwitch® PSE tests to screen for prostate cancer without defaulting to invasive testing.

Read More

Telehealth in Urology 2024

Mark N. Painter, CPMA, discusses the current landscape of telehealth in Urology, including billing and coding changes anticipated for 2024. Over the course of his presentation, Mr. Painter touches on:

Billing for Audio-Visual versus Audio-Only Visits
Private-Payer Telehealth Coverage
Urology-Specific Uses for Telehealth
Benefits of Telehealth for Patient and Physician
Potential Pitfalls of Telehealth in Urology

Mr. Painter concludes that supplementing traditional practice with telehealth is an overall benefit for physician, patient, and practice.

Read More

HIFU Bill Coding 2021

Mark N. Painter, CPMA, managing partner of PRS Consulting LLC, the CEO of PRS Urology Service Corporation, the Vice President of Coding and Reimbursement Information for Physician Reimbursement Systems, Inc., and CEO of Relative Value Studies, Inc., discusses changes to Medicare billing in 2021, covering HIFU (high intensity-focused ultrasound) and detailing how the procedure is reimbursed. He details how the new CPT code for 2021, code 55880, is used for ablation of malignant prostate tissue, transretally approached, using high intensity-focused ultrasound (HIFU) and ultrasound guidance. Mr. Painter details how Medicare has set up facility payments: HIFU can only be billed once per date of service, and many Medicare carriers still consider HIFU as a non-covered service. Also, if the HIFU is done at a non-participating facility, it becomes patient responsibility. The new code does not allow for co-surgeons or assistant surgeons. He points out that there is an established fee schedule for facilities and appropriate values for the code, and advises to look at coverage rules and to keep an eye on individual carriers to see whether they will follow NGS moving forward or not. Mr. Painter also advises to check with each payer before providing this service to find where coverage is, where patient responsibilities lie, and to juggle that with your charges and reimbursement activity.

Read More
  • 1
  • 2

Join the GRU Community

- Why Join? -